|
04 May 2022 |
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
|
|
04 May 2022 |
Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
|
|
04 May 2022 |
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
|
|
04 May 2022 |
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
|
|
04 May 2022 |
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
|
|
03 May 2022 |
Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
|
|
02 May 2022 |
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
|
02 May 2022 |
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
|
|
02 May 2022 |
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
|
|
02 May 2022 |
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
|
|
02 May 2022 |
Ingenia Therapeutics & Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases
|
|
02 May 2022 |
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
|
|
02 May 2022 |
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
|
|
02 May 2022 |
HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
|
|
02 May 2022 |
Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
|
|
02 May 2022 |
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
|
|
02 May 2022 |
Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors
|
|
01 May 2022 |
Inmagene Receives FDA's IND Clearance for OX40 Antagonist
|
|
01 May 2022 |
U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
|
|
01 May 2022 |
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
|
